Somchai Leelakusolvong

Somchai Leelakusolvong

Auto-generated profile, based on publicly available information

Somchai Leelakusolvong

Division of Gastroenterology, Department of Medicine Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2014 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
KGKhean Lee Goh
Khean Lee Goh
MCMyung Gyu Choi
Myung Gyu Choi
WHWilliam Ping I Hsu
William Ping I Hsu
HCHoon Jai Chun
Hoon Jai Chun
VMVarocha Mahachai
Varocha Mahachai
JLJaw Town Lin
Jaw Town Lin

14 December 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
MMMonthira Maneerattanaporn
Monthira Maneerattanaporn
RPRapat Pittayanon
Rapat Pittayanon
TPTanisa Patcharatrakul
Tanisa Patcharatrakul
CBChalermrat Bunchorntavakul
Chalermrat Bunchorntavakul
SSSiam Sirinthornpanya
Siam Sirinthornpanya
WPWanich Piyanirun
Wanich Piyanirun
Click on the article title to read more.

30 September 2024 in Clinical Endoscopy
Verified
Journal Article
Open access
TSTharathorn Suwatthanarak
Tharathorn Suwatthanarak
CPChainarong Phalanusitthepa
Chainarong Phalanusitthepa
CTChatbadin Thongchuam
Chatbadin Thongchuam
TAThawatchai Akaraviputh
Thawatchai Akaraviputh
VCVitoon Chinswangwatanakul
Vitoon Chinswangwatanakul
JWJitladda Wasinrat
Jitladda Wasinrat
Background/Aims: Achalasia is a rare esophageal motility disease, for which peroral endoscopic myotomy (POEM) has emerged as a promising treatment option; however, recurrence remains a challenge. Timed barium esophagography (TBE) is a useful diagnostic tool and potential outcome predictor of achalasia. This study aimed to determine predictive tools for recurrence after POEM.Methods: This retrospective study enrolled achalasia patients who underwent POEM between January 2015 and December 2021. Patients were categorized into two groups using the 1-month post-POEM Eckardt scores and TBE: the discordant group (Eckardt score improved >50%, TBE decreased 50%). Recurrence was defined as a reincrease in the Eckardt score to more than three during follow-up.Results: Complete medical records were available in 30 patients who underwent POEM. Seventeen patients (56.7%) were classified into the discordant group, while 13 patients (43.3%) were in the concordant group. The overall recurrence rate was 11.9% at 1-year, increasing to 23.8% during the extended follow-up. The discordant group had a 6.87 fold higher recurrence rate than the concordant group (52.9% vs. 7.7%, p=0.017).Conclusions: These results strongly suggest that combining the Eckardt score with TBE can effectively predict recurrent achalasia after POEM. Patients in the discordant group had an elevated risk.

26 September 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
NPNutchanun Preechakawin
Nutchanun Preechakawin
MMMonthira Maneerattanaporn
Monthira Maneerattanaporn
TGTanawat Geeratragool
Tanawat Geeratragool
PSPrachaya Srivanitchapoom
Prachaya Srivanitchapoom
YPYuvadee Pitakpatapee
Yuvadee Pitakpatapee
SLSomchai Leelakusolvong
Somchai Leelakusolvong
INTRODUCTION: Constipation, a prevalent nonmotor symptom in Parkinson disease (PD), adversely affects patients' quality of life. Prucalopride, a selective serotonin type 4 receptor agonist, has shown efficacy as a treatment of functional constipation, but its role in PD-related constipation remains underexplored. The objective of this study was to assess the efficacy, safety, and quality-of-life impact of prucalopride in PD patients with chronic constipation. METHODS: In this double-blind randomized controlled trial, PD patients with chronic constipation received prucalopride (2 mg) or placebo once daily for 8 weeks. The primary outcome was the change in the number of spontaneous bowel movements (SBMs) per week from baseline to week 8. Secondary outcomes included stool consistency, straining, and changes in Patient Assessment of Constipation-Symptoms and Patient Assessment of Constipation-Quality of Life scores. Parkinsonian motor severity was assessed using the Unified Parkinson Disease Rating Scale. RESULTS: Fifty-seven patients were included (prucalopride = 30, placebo = 27). At week 8, the change in the number of weekly SBMs was significantly larger in the prucalopride group (3.2 ± 2.8) than in the placebo group (1.6 ± 1.9; P = 0.02). Longitudinal analysis confirmed a significantly higher SBM frequency in the prucalopride group throughout the 8-week period ( P = 0.015). Secondary outcomes showed trends toward improvement but no statistically significant differences. No serious adverse events were reported, and Unified Parkinson Disease Rating Scale scores remained unchanged. DISCUSSION: Prucalopride was safe, well-tolerated, and more effective than placebo in increasing bowel movement frequency in PD patients with chronic constipation, supporting its potential as a therapeutic option in this population.

26 March 2026 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
SLSomchai Leelakusolvong
Somchai Leelakusolvong
TCTju Siang Chua
Tju Siang Chua
DQDuc Trong Quach
Duc Trong Quach
AOAndrew Ming‐Liang Ong
Andrew Ming‐Liang Ong
ASAri Syam
Ari Syam
Yeong Yeh LeeYeong Yeh Lee
Yeong Yeh Lee
Background and Aim: Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations for PPI rationalization to healthcare providers in the region. Methods: The SEA PPI Rationalization Working Group is steered by 14 experts practicing across Malaysia, Thailand, Singapore, Vietnam, the Philippines, and Indonesia. The experts convened to review existing evidence and develop recommendations and to conduct an anonymous voting as per the modified Delphi method. Results: Twenty statements were formulated, focusing on areas of (i) extent and impact of PPI overprescription (four statements), (ii) benefits and barriers to PPI rationalization (two statements), (iii) START/STOPP criteria for PPI (nine statements), and (iv) PPI rationalization strategies (five statements). The consensus document underscores the widespread inappropriate long‐term PPI prescription across SEA, which may have adverse clinical outcomes. Although rationalizing PPI use may be beneficial, the experts acknowledge the challenges of implementing PPI rationalization. The experts also outlined specific indications to guide PPI initiation and advised regular review to rationalize a PPI when no longer indicated. This is followed by PPI rationalization strategies, including shared decision‐making, prescribing alginate as a rescue therapy in gastroesophageal reflux disease, and further evaluation for reinitiation of PPI when clinically warranted. Conclusions: This consensus document serves to improve PPI prescribing and deprescribing practices in SEA and to provide recommendations on rationalization strategies.

30 September 2026 in Clinical Endoscopy
Verified
Journal Article
Open access
TSTharathorn Suwatthanarak
Tharathorn Suwatthanarak
SMSiwaree Maneesoi
Siwaree Maneesoi
CTChatbadin Thongchuam
Chatbadin Thongchuam
TAThawatchai Akaraviputh
Thawatchai Akaraviputh
VCVitoon Chinswangwatanakul
Vitoon Chinswangwatanakul
CPChainarong Phalanusitthepa
Chainarong Phalanusitthepa
Background/Aims: Achalasia is an esophageal motility disorder. Peroral endoscopic myotomy is widely used for all subtypes; however, randomized head-to-head evidence comparing the anterior and posterior approaches remains limited. We compared efficacy, safety, and reflux outcomes.Methods: We conducted a single-center, single-blind, prospective randomized controlled trial from February 2023 to August 2024. Twenty-eight patients with achalasia types I–III were randomized to anterior or posterior peroral endoscopic myotomy. The primary outcomes were esophageal acid exposure at 3 months (24-hour pH monitoring) and clinical success (Eckardt score ≤3). The secondary outcomes were procedural parameters, complications, timed barium esophagography, manometry, and reflux esophagitis.Results: Baseline characteristics were comparable between the groups. Procedural metrics and complication rates were similar and mild, with no severe adverse events. At 12 months, both groups showed significant symptom relief, reduced Eckardt scores, and decreased lower esophageal sphincter pressure. Posterior myotomy yielded a higher proportion of abnormal DeMeester scores (57.1% vs. 28.6%, p=0.14), although reflux esophagitis remained mild and comparable between the groups.Conclusions: Posterior peroral endoscopic myotomy demonstrated comparable efficacy, safety, and reflux outcomes. The anterior approach improved clearance on timed barium esophagography; however, both approaches achieved durable symptom control with acceptable safety profiles, supporting posterior myotomy as a valid alternative.